IP Library Granted Patent US 9,012,220
Granted Patent B2
US 9,012,220 · App. 13/128,145 · Granted Apr 21, 2015

Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Inventors: Dirk Buescher (Madrid, ES); Olga De La Rosa (Madrid, ES); Eleuterio Lombardo (Madrid, ES)
Assignee: Cellerix S.A.
C12N5/0653A61K2035/122C12N9/0069C12N2501/70C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,220
App. No.
13/128,145
Granted
Apr 21, 2015
Kind
B2
Abstract

The present invention relates to cells capable of expressing IDO, nucleic acid constructs for expression of IDO, cells comprising said constructs and methods of utilizing said cells in the treatment of diseases. In particular the present invention relates to cells which express IDO in the absence of exposure to IFN-gamma, and to their use in preparation and/or generation of immunomodulatory cells specific for an antigen.

Claims (3)

1. An in vitro method for the preparation and/or generation of CD4+CD25+FoxP3+ T-regulatory cells comprising contacting mesenchymal stem cells with peripheral blood mononuclear cells or peripheral blood leukocytes, wherein the mesenchymal stem cells comprise exogenous nucleic acid constructs comprising indoleamine 2,3-dioxygenase (IDO) nucleic acid sequences operably linked to a constitutive promoter that drives constitutive expression of IDO in the mesenchymal stem cells.

2. A method according to claim 1 wherein said contacting is carried out in the presence of at least one agent selected from the group consisting of LPS, IL-2, IL-4 and GM-CSF.

3. An in vitro method for the preparation and/or generation of CD4+CD25+FoxP3+ T-regulatory cells specific for an antigen, comprising contacting mesenchymal stem cells with peripheral blood mononuclear cells or peripheral blood leukocytes in the presence of said antigen, wherein the mesenchymal stem cells comprise exogenous nucleic acid constructs comprising indoleamine 2,3-dioxygenase (IDO) nucleic acid sequences operably linked to a constitutive promoter that drives constitutive expression of IDO in the mesenchymal stem cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2021
From: TIGENIX, S.A.U.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 058320/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2011
From: BUESCHER, DIRK; DEL LA ROSA, OLGA; LOMBARDO, ELEUTERIO
To: CELLERIX S.A.
Reel/Frame 027267/0286 →
Priority Claims (1)
GB 0820397.8 · Nov 7, 2008 · national
Continuity (1)
Related Publication 20120064031A1 · Mar 15, 2012